Transfusion Medicine Reviews
Volume 21 , Pages S57-S107 , April 2007

Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions

References 

  1. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17:241–251
  2. Chalmers Research Institute. IVIG systematic reviews. Unpublished
  3. Feasby TE. Appropriateness of IVIG—Hematology summaries. Unpublished
  4. Phillips B, Ball C, Sackett D, et al. Levels of evidence. www.eboncall.org/content/levels.html2002;
  5. Browman GP, Newman TE, Mohide EA, et al. Progress of clinical oncology guidelines development using the practice guidelines development cycle: The role of practitioner feedback. J Clin Oncol. 1998;16:1226–1231
  6. Andersen JB, Rasmussen LH, Herning M, et al. Dramatic improvement of severe acute disseminated encephalomyelitis after treatment with intravenous immunoglobulin in a three-year-old boy. Dev Med Child Neurol. 2001;43:136–138
  7. Apak RA, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev. 1999;21:279–282
  8. Assa A, Watemberg N, Bujanover Y, et al. Demyelinative brainstem encephalitis responsive to intravenous immunoglobulin therapy. Pediatrics. 1999;104:301–303
  9. Balestri P, Grosso S, Acquaviva A, et al. Plasmapheresis in a child affected by acute disseminated encephalomyelitis. Brain Dev. 2000;22:123–126
  10. Jaing TH, Lin KL, Chiu CH, et al. Acute disseminated encephalomyelitis in autoimmune hemolytic anemia. Pediatric Neurology. 2001;24:303–305
  11. Kleiman M, Brunquell P. Acute disseminated encephalomyelitis: Response to intravenous immunoglobulin. J Child Neurol. 1995;10:481–483
  12. Nishikawa M, Ichiyama T, Hayashi T, et al. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol. 1999;21:583–586
  13. Pradhan S, Gupta RP, Shashank S, et al. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci. 1999;165:56–61
  14. Shahar E, Andraus J, Savitzki D, et al. Outcome of severe encephalomyelitis in children: Effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol. 2002;17:810–814
  15. Straussberg R, Schonfeld T, Weitz R, et al. Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol. 2001;24:139–143
  16. Hahn JS, Siegler DJ, Enzmann D. Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology. 1996;46:1173–1174
  17. Mariotti P, Batocchi AP, Colosimo C, et al. Multiphasic demyelinating disease involving central and peripheral nervous system in a child. Neurology. 2003;60:348–349
  18. Pittock SJ, Keir G, Alexander M, et al. Rapid clinical and CSF response to intravenous gamma globulin in acute disseminated encephalomyelitis. Eur J Neurol. 2001;8:725
  19. Revel-Vilk S, Hurvitz H, Klar A, et al. Recurrent acute disseminated encephalomyelitis associated with acute cytomegalovirus and Epstein-Barr virus infection. J Child Neurol. 2000;15:421–424
  20. Finsterer J, Grass R, Stollberger C, et al. Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol. 1998;21:258–261
  21. Fox RJ, Kasner SE, Galetta SL, et al. Treatment of Bickerstaff's brainstem encephalitis with immune globulin. J Neurol Sci. 2000;178:88–90
  22. Marchioni E, Marinou-Aktipi K, Uggetti C, et al. Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol. 2002;249:100–104
  23. Nakamura N, Nokura K, Zettsu T, et al. Neurologic complications associated with influenza vaccination: Two adult cases. Intern Med. 2003;42:191–194
  24. Sahlas DJ, Miller SP, Guerin M, et al. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000;54:1370–1372
  25. Rodriguez M, Lennon VA. Immune globulins promote remyelination in the CNS. Ann Neurol. 1990;27:12–17
  26. Cappa M, Bertini E, del Balzo P, et al. High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry. 1994;57:71;[Suppl 69-70]
  27. Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol. 1996;243:117–120
  28. Dalakas MC, Stein DP, Otero C, et al. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol. 1994;51:861–864
  29. DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: A pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999;29:157–160
  30. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: Beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996;26:439–452
  31. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13:79–82
  32. Van Schaik IN, Winer JB, De Haan R, et al. 1. Cochrane Review: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. (Download in two parts). Cochrane Database Syst Rev. 2002;CD001797
  33. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–1077[Pt 4]
  34. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIG in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56:445–449
  35. Thompson N, Choudhary P, Hughes RA, et al. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 1996;243:280–285
  36. Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56:36–39
  37. Van Doom PA, Brand A, Strengers PF, et al. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology. 1990;40:209–212
  38. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838–845
  39. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201
  40. Kubori T, Mezaki T, Kaji R, et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. (Japanese) No to Shinkei. 1999;51:127–135
  41. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med. 1997;23:1144–1149
  42. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve. 1994;17:1494–1495
  43. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000
  44. Al-Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis—Efficacy and safety. J Rheumatol. 2000;27:2498–2503
  45. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis—Four year review of nine cases. Arch Dis Child. 1995;72:25–28
  46. Tsai MJ, Lai CC, Lin SC, et al. Intravenous immunoglobulin therapy in juvenile dermatomyositis. Zhonghua Min Guo Xiao Erke Yi Xue Hui Za Zhi 1997;38:111-5.
  47. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002;61:37–41
  48. Cherin P, Herson Serge. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1994;50–54[57 Suppl]
  49. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: An open study in 11 adult patients. J Rheumatol. 1994;21:1092–1097
  50. Sharma KR, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol. 2002;59:758–765
  51. Cocito D, Ciaramitaro P, Isoardo G, et al. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol. 2002;249:719–722
  52. Krendel DA, Costigan DA, Hopkins LC. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol. 1995;52:1053–1061
  53. Zochodne DW, Isaac D, Jones C. Failure of immunotherapy to prevent, arrest or reverse diabetic lumbosacral plexopathy. Acta Neurol Scand. 2003;107:299–301
  54. Jaradeh SS, Prieto TE, Lobeck LJ. Progressive polyradiculoneuropathy in diabetes: Correlation of variables and clinical outcome after immunotherapy. J Neurol Neurosurg Psychiatry. 1999;67:607–612
  55. Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996;46:100–103
  56. Diener HC, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol. 2001;46:107–109
  57. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group . Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225–230
  58. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326:1123–1129
  59. Nomura T, Hamaguchi K, Hosakawa T, et al. A randomized trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurol Therapeut. 2001;18:68–81
  60. Hughes RAC, Raphael JC, Swan AV, et al. Systematic review: Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev Neurol. 2003;CD002063
  61. Hosokawa T, Hamaguchi K, Tomioka R, et al. Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: A preliminary report. Ther Apher. 1998;2:288–291
  62. Martinez YA, Huerta VM, Olive PM, et al. Treatment of Guillain-Barré syndrome: Immunoglobulins or plasmapheresis?. Neurologia. 1998;134:166–169(Spanish)
  63. El Zunni S, Prakash PS, Saiti KM, et al. Guillain-Barré syndrome (GBS): An appraisal. Cent Afr J Med. 1997;43:99–103
  64. Gurses N, Uysal S, Cetinkaya F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis. 1995;27:241–243
  65. Raphael JC, Chevret S, Hughes RA, et al. 1. Systematic review: Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2001;CD001798;(in 2 parts)
  66. Haupt WF, Rosenow F, van der Ven C, et al. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci. 1996;137:145–149
  67. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol. 2000;247:22–28
  68. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIG: A double-blind, placebo-controlled study. Neurology. 1997;48:712–716
  69. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323–327
  70. van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, et al. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res. 1994;24:162–166
  71. Illum N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: A single blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics. 1990;21:87–90
  72. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678–683
  73. van Schaik IN, van den Berg LH, de Haan R. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2005;CD004429
  74. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology. 1994;44:429–432[3 Pt 1]
  75. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study. Neurology. 2000;55:1256–1262
  76. Leger JM, Chassande B, Musset L, et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebo-controlled study. Brain. 2001;124:145–153[Pt 1]
  77. Van den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248–252
  78. Poehlau D. Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins–interim results on drug safety of an ongoing study. IVIG study group. Mult Scler. 2000;6:S21–S23[Suppl 2]
  79. Fazekas F, Freedman MS, Hartung HP, et al. Prevention of relapse with intravenous immunoglobin study: Initial results of a dose-finding trial in relapsing-remitting multiple sclerosis. European Neurological Society. May 2006;
  80. Sorensen PS, Fazekas F, Lee M. 1. Meta analysis: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: A meta-analysis. Eur J Neurol. 2002;9:557–563
  81. Achiron A, Gabbay U, Gilad R, et al. RRMS: Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology. 1998;50:398–402
  82. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. RRMS: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997;349:589–593
  83. Lewanska M, Siger-Zajdel M, Selmaj K. RRMS: No difference in efficacy of two different doses of intravenous immunoglobulins in MS: Clinical and MRI assessment. Eur J Neurol. 2002;9:565–572
  84. Oztekin NaO. Intravenous immunoglobulin treatment in relapsing-remitting multiple sclerosis: A double blind cross over study. Mult Scler. 1998;4:391
  85. Sorensen PS, Wanscher B, Jensen CV, et al. RRMS: Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998;50:1273–1281
  86. Achiron A, Barak Y, Goren M, et al. Intravenous immune globulin in multiple sclerosis: Clinical and neuroradiological results and implications for possible mechanisms of action. Clin Exp Immunol. 1996;104:67–70[Suppl 1]
  87. Teksam M, Tali T, Kocer B, et al. RRMS: Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: Preliminary report. Neuroradiology. 2000;42:885–889
  88. Hommes OT, Sorensen PS, Fazekas F, et al. for the European Study on Immunoglobulin in Multiple Sclerosis trialists Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial. Mult Scler. 2003;364:1149–1156
  89. Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. Neurology. 2000;55:1135–1143
  90. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514–1522
  91. Poehlau D. Results of double-blind, randomised, placebo-controlled pilot study on the treatment of multiple sclerosis with intravenous immunoglobulin. Eur J Neurol. 1996;3:[Suppl 4]
  92. Gajdos P, Chevret S, Toyka K. 1. Systematic review: Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2003;CD002277
  93. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789–796
  94. Ronager J, Ravnborg M, Hermansen I, et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25:967–973
  95. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve. 2002;26:549–552
  96. Achiron A, Barak Y, Miron S, et al. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve. 2000;23:551–555
  97. Cosi V, Lombardi M, Piccolo G, et al. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand. 1991;84:81–84
  98. Hilkevich O, Drory VE, Chapman J, et al. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharmacol. 2001;24:173–176
  99. Huang CS, Hsu HS, Kao KP, et al. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand. 2003;108:136–138
  100. Wegner B, Ahmed I. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin Neurol Neurosurg. 2002;105:3–8
  101. Wilson JR, Bhoopalam H, Fisher M. Hemolytic anemia associated with intravenous immunoglobulin. Muscle Nerve. 1997;20:1142–1145
  102. Herrmann DN, Carney PR, Wald JJ. Juvenile myasthenia gravis: Treatment with immune globulin and thymectomy. Pediatr Neurol. 1998;18:63–66
  103. Selcen D, Dabrowski ER, Michon AM, et al. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22:40–43
  104. Tagher RJ, Baumann R, Desai N. Failure of intravenously administered immunoglobulin in the treatment of neonatal myasthenia gravis. J Pediatr. 1999;134:233–235
  105. Bassan H, Muhlbaur B, Tomer A, et al. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis. Pediatr Neurol. 1998;18:181–183
  106. Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124:437–443[Pt 2]
  107. Pless M, Ronthal M. Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology. 1996;46:583–584
  108. Pranzatelli MR, Tate ED, Kinsbourne M, et al. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: Cerebellar atrophy, multiphasic relapses, and response to IVIG. Mov Disord. 2002;17:1387–1390
  109. Sugie H, Sugie Y, Akimoto H, et al. High-dose i.v. human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome. Acta Paediatr. 1992;81:371–372
  110. Yiu VW, Kovithavongs T, McGonigle LF, et al. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol. 2001;24:72–74
  111. Penzien JM, Speck S, Vassella F. Opsoclonus polymyoclonia syndrome. Acta Paediatr. 1993;82:319–320
  112. Petruzzi MJ, de Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr. 1995;127:328–329
  113. Eiris J, del Rio M, Castro-Gago M. Immune globulin G for treatment of opsoclonus-polymyoclonus syndrome. J Pediatr. 1996;129:175
  114. Borgna-Pignatti C, Balter R, Marradi P, et al. Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus. J Pediatr. 1996;129:179–180
  115. Fisher PG, Wechsler DS, Singer HS. Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol. 1994;10:309–312
  116. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002;249:1370–1377
  117. Lunn MP, Nobile-Orazio E. 1. Cochrane review: Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2003;CD002827
  118. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40:792–795
  119. Mariette X, Chastang C, Clavelou P, et al. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1997;63:28–34
  120. Dispenzieri A. POEMS syndrome. Hematology (Am Soc Hematol Educ Program). 2005;360–367
  121. Huang CC, Chu CC. Poor response to intravenous immunoglobulin therapy in patients with Castleman's disease and the POEMS syndrome. J Neurol. 1996;243:726–727
  122. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999;354:1153–1158
  123. Benito-Leon J, Lopez-Rios F, Rodriguez-Martin FJ, et al. Rapidly deteriorating polyneuropathy associated with osteosclerotic myeloma responsive to intravenous immunoglobulin and radiotherapy. J Neurol Sci. 1998;158:113–117
  124. Henze T, Krieger G. Combined high-dose 7S-IgG and dexamethasone is effective in severe polyneuropathy of the POEMS syndrome. J Neurol. 1995;242:482–483
  125. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467–474
  126. Granata T, Fusco L, Gobbi G, et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology. 2003;61:1807–1810
  127. Korn-Lubetzki I, Bien CG, Bauer J, et al. Rasmussen encephalitis with active inflammation and delayed seizures onset. Neurology. 2004;62:984–986
  128. Frucht S. Dystonia, athetosis, and epilepsia partialis continua in a patient with late-onset Rasmussen's encephalitis. Mov Disord. 2002;17:609–612
  129. Villani F, Spreafico R, Farina L, et al. Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis. Neurology. 2001;56:248–250
  130. Leach JP, Chadwick DW, Miles JB, et al. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology. 1999;52:738–742
  131. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–1876

PII: S0887-7963(07)00003-X

doi: 10.1016/j.tmrv.2007.01.002

Transfusion Medicine Reviews
Volume 21 , Pages S57-S107 , April 2007

Article Tools